Clinical Trials Logo

Filter by:
NCT ID: NCT04996082 Not yet recruiting - Clinical trials for Validation of Raman Spectroscopy Usefulness in Systemic Sclerosis

Skin Fibrosis Analysis by Raman Spectroscopy in Systemic Sclerosis

RAMSES
Start date: October 2021
Phase:
Study type: Observational

Systemic sclerosis (SSc) is a rare connective tissue disease characterized by a high clinical heterogeneity with unpredictable evolution that could engage functional and life-threatening prognosis. Most of patients develop skin fibrosis gradually spreading. Two clinical distinct forms are described according to the extension of skin fibrosis: limited (lSSc) and diffuse (dSSc) SSc. It is now admitted that a spreading of skin fibrosis is associated with poor prognosis. This disease can be complicated by pulmonary arterial hypertension (PAH), interstitial lung disease (ILD) and scleroderma renal crisis (SRC) representing the main causes of death in SSc. Usually, PAH is associated with lSSc, and ILD and SRC are associated with dSSc. Prognosis is also different regarding skin phenotype with a higher mortality rate in dSSc. An easy score, called modified Rodnan skin score, is commonly used in clinical practice to evaluate the spreading and severity of skin fibrosis, but this score is hardly reproducible. Ultrasound can be used to measure skin thickness and is more reproducible than the Rodnan skin score. Nevertheless, non-invasive analysis of fibrosis composition in different areas is not possible with these two technics. Thus, in this study we will investigate Raman spectroscopy, a non-invasive technic based on the interaction of a low-intensity laser with matter.

NCT ID: NCT04995965 Recruiting - Clinical trials for Nfections, Enterobacterial

Infections With Enterobacteria Producing Carbapenemases at the University Hospitals of Strasbourg

CARBA
Start date: August 6, 2021
Phase:
Study type: Observational

Infections with enterobacteria producing carbapenemases at the University Hospitals of Strasbourg - descriptive epidemiology and risk factors for infection in the event of colonization There is a worrying situation of an increase in the number of patients colonized with carbapenemase-producing Enterobacteriaceae (CPE) at HUS. 7 to 15% of patients colonized with EPC would develop an infection with EPC. The cohorts published mainly concern patients hospitalized in intensive care. The associated mortality reported in the literature is high (> 25%) and greater than that associated with infection with the same bacterium sensitive to carbapenems.

NCT ID: NCT04995822 Active, not recruiting - Hip Fractures Clinical Trials

Post Market Clinical Follow-up of EUROSTEM Femoral Stem

Start date: May 21, 2021
Phase:
Study type: Observational

EUROSSTEM is intended for use in primary and revision total hip replacement surgery. Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. As part of post market vigilance, EUROS will collect data on EUROSTEM performances and safety

NCT ID: NCT04995588 Recruiting - Systemic Sclerosis Clinical Trials

Systemic Sclerosis and Innate T Cells

Start date: February 28, 2022
Phase: N/A
Study type: Interventional

Innate T cells (ITC) are decreased in systemic sclerosis (SS) and an early lymphocyte innateness has been reported. In the other part, ITC are implicated on inflammatory process, including the IL-33/ST2 axis, which is also involved in ScS endotheliopathy. Data are however scarce and physiopathological mechanisms have not been assessed to date. The investigators hypothesize a global lymphocyte innateness in SSc, linked to a chronic ITC stimulation by innate signals leading to ITC exhaustion, and their potential role in endotheliopathy and fibroblast activation in SSc.

NCT ID: NCT04995549 Completed - Clinical trials for Unrecognized Condition

SKin Uncertainties Modeling

SKUM
Start date: November 26, 2021
Phase: N/A
Study type: Interventional

The study is based on measurement device and will provide a database of viscoelastic properties of the forearm skin among healthy volunteers. These data will be used to develop a mathematical model representative of the mechanical behavior of the skin.

NCT ID: NCT04995523 Active, not recruiting - Clinical trials for Non-Small-Cell Lung Carcinoma

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

ARTEMIDE-01
Start date: September 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.

NCT ID: NCT04994795 Recruiting - Clinical trials for Non-small Cell Lung Cancer Metastatic

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

DEEP-Lung-IV
Start date: August 21, 2021
Phase:
Study type: Observational

Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.

NCT ID: NCT04994730 Recruiting - Cancer Clinical Trials

Exenteration: Quality of Life Study and Rehabilitation Rate According to the Reconstruction Technique (ETRE)

ETRE
Start date: May 25, 2021
Phase:
Study type: Observational

Prospective monocentric quality of life study. Including all patients who have been exentered at the Institut Curie Paris, from January 2004 to December 2019, proposing to compare the reported quality of life of patients according to the reconstruction technique they have undergone. The sponsor will evaluate the quality of life of our patients by means of two validated questionnaires, in French, in the context of ENT surgery: the FACT-G and FACT-MBIS questionnaires.

NCT ID: NCT04994717 Recruiting - Clinical trials for Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Start date: November 2, 2021
Phase: Phase 3
Study type: Interventional

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.

NCT ID: NCT04994665 Recruiting - Obesity Clinical Trials

Evaluation of Omentopexy on Gastro-oesophageal Reflux Following Sleeve Gastrectomy

Sleevepexie
Start date: December 7, 2021
Phase: N/A
Study type: Interventional

The aim of the study is to assess impact of omentopexy on de novo gastro-oesophageal reflux disease (GERD) after sleeve gastrectomy. This will be assess 2 years postoperatively. This study is a prospective, multicentric, randomized trial. Five hundred twenty six patients should be included with 263 in each arm. First arm will include patients who have a sleeve gastrectomy. The second arm will include patients who have sleeve gastrectomy with omentopexy. Two years after surgery , it will be collected a CARLSSON score and BAROS score (quality of life). The main objective is to show that omentopexy decreases the rate of de novo GERD after sleeve gastrectomy at 2 years postoperatively without the use of Proton-Pump Inhibitors (PPIs)